Gossamer Bio, Inc. (GOSS) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Gossamer Bio, Inc.'s filing signal turned negative.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing seralutinib for pulmonary hypertension (PH), including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). The company's strategy centers on advancing seralutinib through regulatory pathways, aiming for potential FDA approval by the end of 2027. Gossamer Bio has a collaboration agreement with Chiesi Farmaceutici S.p.A. for the global development and commercialization of seralutinib. Seralutinib is an inhaled, small molecule inhibitor targeting PDGFR, CSF1R, and c-KIT pathways, designed to reverse pathological remodeling in the pulmonary vasculature. The company also has an option to acquire RT234, an investigational inhaled, on-demand PDE5 inhibitor for PAH and PH-ILD.

Revenue is primarily generated from the Chiesi Collaboration Agreement, which includes a one-time development cost reimbursement payment for licenses and ongoing cost-sharing payments for research and development services. Future revenue may come from license fees, milestone payments, product sales, and royalties.